U.S. Doctors Review Pfizer’s Paxlovid for Less Dangerous COVID Patients

May 28 (Reuters) – The use of Paxlovid by the Pfizer Inc. (PFE.N) against the COVID-19 virus has increased this week, but after the U.S. Public Health Agency warned that symptoms could recur after people finished, some doctors reintroduced pills for low-risk patients. reviewed. The course of the drug, then they should be isolated a second time.

More quarantine time “people didn’t like it,” the doctor said. Sandra Kemmerley, an infectious disease specialist at Ochsner Health in New Orleans, told Reuters. “For people who aren’t really at risk … I’d advise you not to take it.”

Pfizer’s permission to treat newly infected Paxlovids in high-risk groups to prevent serious illnesses has increased as infections have increased. According to the government, more than 162,000 courses were distributed last week – an average of 33,000 a week since the drug began late last year. Biden’s administration has demanded the widespread use of Paxlovid, which the government bought and provided free of charge.

Sign up now for FREE unlimited access to Reuters.com

However, there were more reports of people returning to Paxlovid a few days after their symptoms subsided and completing their five-day pill regimen.

On Tuesday, the Centers for Disease Control and Prevention issued a recommendation that Paxlovid users should be isolated for a second five days if symptoms worsen, citing fears that the virus could spread. read more

“I am ashamed to give it to low-risk and non-severely ill people, especially those who have been vaccinated and vaccinated,” the doctor said. Bruce Farber, head of public health and epidemiology for Northwell Health. According to him, he still recommends Paxlovid to people who are in poor health or over 75 years old.

Pfizer, in an email, said he was monitoring the data, but believes that the return of the detected virus is rare and not unique to his medication. “To date, we have not seen any resistance in patients treated with Paxlovid,” the spokesman said.

Ambulance factors are at risk of using it only for prescriptions that should be used for newly infected people, but doctors say many other people have sought the drug.

“We get a lot of requests – maybe someone is traveling and they want to take it whenever they want,” the doctor said. Tara Vijayan, Infectious Diseases Specialist, UCLA Health, Los Angeles. “We didn’t just offer it as a job.”

The CDC also said it was unclear whether the recurring symptoms were related to Paxlovid or just part of the natural trajectory of COVID-19. The agency did not raise any specific concerns about its health effects.

“COVID has gone through a similar stuttering course in history – people feel better one day and then get worse the next day, but I can say that we have not seen these relapse symptoms from other COVID treatments,” Vijayan said, referring to such therapies. monoclonal antibodies.

“Patients recover, usually very mildly,” the doctor said. Earl Strum, Medical Director of USC Revenge Medical Staff Health in Los Angeles.

Some people ask how much Paxlovid is helping, given the large number of people who have been infected or vaccinated against COVID-19. A study of patients with COVID who were approved for the drug in December, were not vaccinated, and had conditions such as diabetes showed an 88% reduction in hospitalizations or deaths.

The Delta variant was popular at the time, but since then it has been replaced by the transmissive Omicron.

“There’s a lot more basic immunity around. There are still a lot of infections, but they’re not that serious,” Farworth said of Northwell.

He estimated the rate of COXID recurrence associated with Paxlovid to be about 10% – higher than the 3-4% rate reported in Pfizer drug tests.

Jason Gallagher, an infectious disease expert at Temple University’s School of Pharmacy, says the uprising will not reduce the drug’s effectiveness. “It prevents you from going to the hospital … if you have symptoms after you stop taking it, it stinks, but the overall medication has been successful,” he said.

Sign up now for FREE unlimited access to Reuters.com

Dina Bisley’s Los Angeles Report Edited by Caroline Humer and Matthew Lewis

Our Standards: Thomson Reuters Trust Principles.


Leave a Comment

Your email address will not be published.